Compare CZNC & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CZNC | ADCT |
|---|---|---|
| Founded | 1864 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.0M | 445.2M |
| IPO Year | 2009 | 2019 |
| Metric | CZNC | ADCT |
|---|---|---|
| Price | $20.89 | $3.44 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $23.50 | $7.75 |
| AVG Volume (30 Days) | 26.1K | ★ 1.1M |
| Earning Date | 05-12-2026 | 05-04-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | 7.64 | ★ 30.86 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | $3.11 | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $1,052.50 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $18.02 | $1.35 |
| 52 Week High | $24.12 | $4.98 |
| Indicator | CZNC | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 31.91 | 33.93 |
| Support Level | $19.82 | $3.40 |
| Resistance Level | $22.48 | $3.59 |
| Average True Range (ATR) | 0.52 | 0.22 |
| MACD | -0.23 | -0.04 |
| Stochastic Oscillator | 4.71 | 9.74 |
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).